PUBLIC COMPANY
saveRuijin Hospital
updated 5mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
0
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- EP1An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
- EP1First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure
- EP1Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
- —Predicting DBS Outcomes in Dystonia Using Wearable Gait Sensors
- phase2HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- N/ARobotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
- N/APSA Versus STN DBS for TD-PD
- N/AThe Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
🐶 Hiring Signal
News
- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerNovartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager that showed early clinical promise in autoimmune disease. The deal, which includes up to $7.2 billion i…fiercebiotech · 3d ago
comments(0)
5-min edit window · permanent after that